News | April 27, 2008

DuraHeart LVAS Implant Results Show Improved Survival

April 28, 2008 - Terumo Heart will present data on its DuraHeart LVAS, a circulatory support device intended to provide cardiac support for patients who are at risk of death due to end-stage left ventricular failure, which indicates the device provides safe and reliable long-term circulatory support with improved survival.

Chisato Nojiri, M.D., Ph.D., CEO for Terumo Heart, presented at the ISHLT meeting in Boston results from the report entitled "Long Term Circulatory Support with the DuraHeart Mag-Lev Centrifugal LVAS for Advanced Heart Failure Patients Eligible for Transplantation: European Experience."

The presentation concluded that the DuraHeart LVAS provides safe and reliable long-term circulatory support with improved survival. High device reliability and a low stroke rate despite less intensive anticoagulation offer easier out-of-hospital management.

The presentation summarized results of 55 patients (33 in the CE-mark trial and 22 after market launch) who were implanted with the DuraHeart (LVAS) Left Ventricular Assist System between January 2004 and March 2008. The average duration of support was 214 /- 226 days with a cumulative duration of 32 years. The Kaplan-Meier (K-M) survival was 82 percent at 6 months and 77 percent at 1 year. Eighteen patients (33 percent) were transplanted at 181 /- 135 days. Thirteen patients (24 percent) were supported > 1 year with the mean support duration of 568 /- 183 days and 2 were supported > 2 years. Twenty-seven patients (49 percent) remain on support for 274 /- 276 (17-1,001) days.

K-M survival at 1 year in the CE-mark trial was 100 percent in patients

The DuraHeart LVAS is not available for sale in the U.S., but Terumo Heart has received conditional approval from the FDA to commence a multicenter pivotal trial in the United States and plans to conduct the first implants at its principal investigational sites in the near future.

For more information: www.terumo.com

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD)| April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD)| March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD)| March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD)| March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init